SCHEMBL2460065

SCHEMBL2460065

CN(C)CCOC1CC(C2=C3C=NC=C[N+]3(N)C(c3cccc(OCc4ccccc4)c3)=N2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 7/20 0.36
NAAA Q02083 2/20 0.35
TNK2 Q07912 1/20 0.35
PDE10A Q9Y233 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
MCHR1 Q99705 1/20 0.33
TMEM97 Q5BJF2 2/20 0.32
SIGMAR1 Q99720 2/20 0.32
DYRK3 O43781 1/20 0.31
MAP4K4 O95819 1/20 0.31
PIM1 P11309 1/20 0.31
RPS6KB1 P23443 1/20 0.31
CSNK2A1 P68400 1/20 0.31
PKN2 Q16513 1/20 0.31
PIM3 Q86V86 1/20 0.31
BRSK1 Q8TDC3 1/20 0.31
AURKB Q96GD4 1/20 0.31
HIPK2 Q9H2X6 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457535 0.88 IGF1R (0.38) IGF1RTNK2PDE10A
SCHEMBL2460547 0.87 IGF1R (0.48) IGF1RTNK2PDE10ADYRK3MAP4K4
SCHEMBL2460659 0.85 IGF1R (0.47) IGF1RTNK2PDE10ARPS6KB1AURKB
SCHEMBL2457673 0.84 DHODH (0.37) IGF1RNAAATNK2
SCHEMBL2460636 0.84 IGF1R (0.39) IGF1RTNK2PDE10A
SCHEMBL2459888 0.83 IGF1R (0.41) IGF1RTNK2DYRK3MAP4K4RPS6KB1
SCHEMBL2460270 0.83 IGF1R (0.42) IGF1RTNK2PDE10ARPS6KB1AURKB
SCHEMBL2461512 0.83 IGF1R (0.40) IGF1RTNK2
SCHEMBL2459711 0.83 IGF1R (0.41) IGF1RTNK2PDE10ARPS6KB1AURKB
SCHEMBL2457195 0.82 IGF1R (0.38) IGF1RTNK2DYRK3MAP4K4RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 IGF1R 1/4885NAAA 4804/4885TNK2 760/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885NAAA 4804/4885TNK2 760/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885NAAA 4804/4885TNK2 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.